On Monday, Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) opened lower -3.70% from the last session, before settling in for the closing price of $20.55. Price fluctuations for ARCT have ranged from $17.52 to $45.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 310.16%. Company’s average yearly earnings per share was noted -209.47% at the time writing. With a float of $24.63 million, this company’s outstanding shares have now reached $26.83 million.
Considering the fact that the conglomerate employs 180 people, you should pay attention to its efficiency factor.
Arcturus Therapeutics Holdings Inc (ARCT) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Arcturus Therapeutics Holdings Inc is 8.53%, while institutional ownership is 103.67%. The most recent insider transaction that took place on Jun 12 ’24, was worth 1,601,500. In this transaction Chief Financial Officer of this company sold 50,000 shares at a rate of $32.03, taking the stock ownership to the 220,526 shares. Before that another transaction happened on Jun 05 ’24, when Company’s Chief Scientific Officer & COO sold 114 for $45.00, making the entire transaction worth $5,130. This insider now owns 447,334 shares in total.
Arcturus Therapeutics Holdings Inc (ARCT) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -0.61 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -1.69) by 1.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.27 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -209.47% per share during the next fiscal year.
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) Trading Performance Indicators
Check out the current performance indicators for Arcturus Therapeutics Holdings Inc (ARCT). In the past quarter, the stock posted a quick ratio of 3.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.69. Likewise, its price to free cash flow for the trailing twelve months is 50.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.57, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -1.59 in one year’s time.
Technical Analysis of Arcturus Therapeutics Holdings Inc (ARCT)
Compared to the last year’s volume of 0.51 million, its volume of 0.37 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 11.32%. Additionally, its Average True Range was 1.74.
During the past 100 days, Arcturus Therapeutics Holdings Inc’s (ARCT) raw stochastic average was set at 4.17%, which indicates a significant decrease from 16.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.22% in the past 14 days, which was lower than the 88.06% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $27.58, while its 200-day Moving Average is $29.25. Nevertheless, the first resistance level for the watch stands at $20.35 in the near term. At $20.91, the stock is likely to face the second major resistance level. The third major resistance level sits at $21.74. If the price goes on to break the first support level at $18.96, it is likely to go to the next support level at $18.13. Now, if the price goes above the second support level, the third support stands at $17.57.
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) Key Stats
There are currently 26,932K shares outstanding in the company with a market cap of 532.94 million. Presently, the company’s annual sales total 166,800 K according to its annual income of -29,730 K. Last quarter, the company’s sales amounted to 38,010 K and its income totaled -26,820 K.
